Arseus NV (RCUS.BR)
21.95EUR
11:35am EDT
€2.12 (+10.69%)
€19.83
€20.73
€22.44
€20.73
494,244
55,596
€22.44
€12.28
About
Overall
| Beta: | 0.57 |
| Market Cap (Mil.): | €621.84 |
| Shares Outstanding (Mil.): | 31.36 |
| Dividend: | 0.45 |
| Yield (%): | 2.27 |
Financials
| RCUS.BR | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 14.12 | 27.94 | 37.87 |
| EPS (TTM): | 1.40 | -- | -- |
| ROI: | 11.15 | 9.18 | 18.70 |
| ROE: | 19.16 | 12.46 | 19.53 |
UPDATE 2-Medical supplies group Arseus optimistic on second-half
* Says starts strategic review of two units (Adds detail on strategic review, share reaction, analyst comment)
Arseus H1 profit beats expectations led by drug ingredients
BRUSSELS, Aug 2 - Belgian medical equipment maker Arseus posted better-than-expected core profit in the first half of 2013, led by a surge in profitability at its Fagron unit which sells medical ingredients to pharmacies.
BRIEF-Arseus : Arseus divests Belgium based Dorge Medic
BRUSSELS, July 4 - Arseus NV : * Arseus divests Belgium based Dorge Medic
Drug compounding supplier Arseus buys U.S.-based Freedom Pharma
BRUSSELS - Belgium-based Arseus , the world's biggest supplier of ingredients to pharmacists so they can mix up their own versions of drugs, bought U.S.-based Freedom Pharmaceuticals for an undisclosed sum, it said on Thursday.
Drug compounding supplier Arseus buys U.S.-based Freedom Pharma
BRUSSELS, April 25 - Belgium-based Arseus , the worlds biggest supplier of ingredients to pharmacists so they can mix up their own versions of drugs, bought U.S.-based Freedom Pharmaceuticals for an undisclosed sum, it said on Thursday.
Drug ingredient firm Arseus says Q1 sales rise
BRUSSELS, April 9 - Belgo-Dutch medical firm Arseus said on Tuesday growth in its drug ingredients business offset declines in its dental business in the first quarter.
Drug ingredient firm Arseus says margins to improve in 2013
BRUSSELS, Feb 6 - Belgo-Dutch medical firm Arseus , the world's biggest seller of drug ingredients to pharmacists, expects its profit margin to improve this year after it beat profit expectations in 2012, it said on Wednesday.

Estimates